Literature DB >> 7000116

Lymphocyte supernatants and the electrophoretic mobility of erythrocytes: further experience of cancer diagnosis.

J E Dyson, A P Watkinson, W G Jones, P J Corbett, C A Joslin.   

Abstract

A double-blind trial of the tanned-erythrocyte electrophoretic mobility test for cancer has been carried out. This included 70 normal subjects as controls, 61 subjects with disease other than cancer, and 229 cancer patients. Slowing values generally increased in the order given, with certain diseases having values within the range positive for cancer. Exposure to viral infection also tended to produce false positives. Slowing values above 50%, however, appear to be definitely associated with cancer. For the middle range of slowing values (25-50%) there is some overlap between the 3 groups, so that a statistical probability of the presence of malignancy is available from the test. With slowing values below 25% there is little likelhood of cancer. Tumour type influences the test result, as does, to a lesser extent, tumour bulk.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000116      PMCID: PMC2010423          DOI: 10.1038/bjc.1980.257

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Macrophage-electrophoretic-mobility (M.E.M.) test for malignant disease. An independent confirmation.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

2.  The effects of stimulated lymphocyte supernatants on the electrophoretic mobility distribution of peritoneal macrophages.

Authors:  H R Petty; B R Ware; H G Remold; R E Rocklin
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

3.  Lymphocyte sensitisation: an in-vitro test for cancer?

Authors:  E J Field; E A Caspary
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

4.  The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors.

Authors:  A W Preece; P A Light
Journal:  Clin Exp Immunol       Date:  1974-12       Impact factor: 4.330

5.  An assessment of the macrophage electrophoretic mobility test (MEM) in cancer diagnosis.

Authors:  E H Crozier; M E Hollinger; B E Woodend; J H Robertson
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

6.  Macrophage electrophoretic mobility (MEM) with myelin basic protein.

Authors:  G A Rawlins; J M Wood; K D Bagshawe
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

7.  Failure to obtain positive MEM tests in either cell-mediated immune conditions in the guinea-pig or in human cancer.

Authors:  H Arvilommi; M M Dale; H N Desai; J L Mongar; M Richardson
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

8.  Evaluation and development of the macrophage electrophoretic mobility (MEM) test for malignant disease.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

9.  Effect of lymphocyte supernatants on the electrophoretic mobility of erythrocytes: significance in cancer diagnosis.

Authors:  J E Dyson; P J Corbett
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.